We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Metabolon Appoints Chief Scientific Officer

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Metabolon Appoints Chief Scientific Officer"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Metabolon, Inc. has announced the addition of Dr. Michael Milburn as its Chief Scientific Officer.  Dr. Milburn was most recently Senior Vice President of Research and Corporate Development at Sirtris Pharmaceuticals
“Mike's extensive background and proven leadership ability in drug discovery and development will be valuable as we continue our biomarker discovery projects and expand our business interest into various phases of product development,” said Dr. John Ryals, president and CEO of Metabolon.
Dr. Milburn brings 15 years of experience in biotech and pharmaceutical companies to Metabolon. At Sirtris, he led the preclinical/clinical development of projects in the areas of metabolic disease and neurodegeneration. 

Prior to Sirtris, Dr. Milburn was Senior Vice President of Research at Plexxikon, where he was responsible for the development of the company's proprietary high-throughput co-crystallography drug discovery platform. 

He has also held positions at Structural Genomix and GlaxoSmithKline.  Dr. Milburn received his Ph.D. in Structural Chemistry at the University of California, Berkeley, and was a Research Fellow at Harvard Medical School for his postdoctoral work.
“Metabolon is the leading company in the development and application of metabolomics, and I look forward to building on its success,” said Dr. Milburn. 

“Metabolon's ability to identify all of the human metabolites within a disease context or drug effect represents a fast path to identifying new disease diagnostics or alternative therapeutic uses for drug candidates.”